Vitruvia Medical AG

Half yearly results as per June 30, 2026
Inkl. Management Report

Figures in CHF

VITRUVIA MEDICAL AG, ANGLIKON

Bilanz per 30. Juni 2026

	30.06.2026 CHF	30.06.2025 CHF
AKTIVEN		
Umlaufvermögen		
Flüssige Mittel	5'136.28	2'030.31
Forderungen ggn. Tochtergesellschaften	0.00	0.00
Sonstige Forderungen	1'688.80	2'046.45
Aktive Rechnungsabgrenzungen	0.00	0.00
	6'825.08	**4'076.76**
Anlagevermögen		
langfristige Finanzanlagen	188'641.07	236'750.00
Beteiligungen	2'327'019.19	1'607'819.00
	2'515'660.26	**1'844'569.00**
TOTAL AKTIVEN	**2'522'485.34**	**1'848'645.76**
PASSIVEN		
Kurzfristiges Fremdkapital		
Verbindlichkeiten aus Lieferungen und Leistungen	37'415.48	4'602.36
Verbindlichkeiten ggn. Nahenstehende	169'211.00	60'000.00
kurzfristige Finanzverbindlichkeiten	0.00	0.00
Passive Rechnungsabgrenzungen	106'200.00	83'355.12
	312'826.48	**147'957.48**
Langfristiges Fremdkapital		
Steuerrückstellung	835.00	0.00
Wandelanleihe - 2% 2022 - 2025	0.00	1'255'000.00
	835.00	**1'255'000.00**
Eigenkapital		
Aktienkapital	3'767'367.00	2'511'578.00
Reserven aus Kapitaleinlagen	10'979'786.25	10'979'786.25
Verlustvortrag	-12'664'115.36	-12'972'786.09
Jahresgewinn (Verlust Vorjahr)	125'785.97	-72'889.88
	2'208'823.86	**445'688.28**
TOTAL PASSIVEN	**2'522'485.34**	**1'848'645.76**

VITRUVIA MEDICAL AG, ANGLIKON

Erfolgsrechnung 1. Januar - 30. Juni 2026

Vorjahr 01. Januar 2025 - 30. Juni 2025

	2026 CHF	2025 CHF
Verwaltungsaufwand		
Verwaltungsaufwand	0.00	0.00
Rechts- und Beratungsaufwand	-7'674.40	-4'677.00
Organisationskosten	-20'532.30	-17'521.27
Büro- und Verwaltungskosten	-11'566.04	-6'807.87
	-39'772.74	**-29'006.14**
Finanzertrag		
Zinserträge	0.00	0.00
Darlehenszinsen (aktiv)	0.00	4'630.11
Beteiligungsertrag	181'868.70	0.00
	181'868.70	**4'630.11**
Finanzaufwand		
Bankzinsen und -spesen / Depotgebühren	-41.10	-288.85
Darlehenszinsen (passiv)	3'321.45	-37'650.00
Kursdifferenzen	1'134.74	-9'375.00
	4'415.09	**-47'313.85**
Ergebnis Finanzrechnung	**186'283.79**	**-42'683.74**
Wertberichtigungen Darlehen / Beteiligungen	0.00	0.00
Periodenfremder Ertrag	171.32	0.00
Ergebnis vor Steuern	**146'682.37**	**-71'689.88**
Steuern	-20'896.40	-1'200.00
Ergebnis nach Steuern	**125'785.97**	**-72'889.88**

vitruvia
WE SUSTAIN ADDED VALUES

Management Report as of June 30, 2026

Vitruvia Medical AG achieved results in line with expectations in the first half of 2026. The Board of Directors confirms the forecast for the full year.

Vitruvia Medical AG looks back on a successful first half of 2026 and remains fully on track with its business development. Particularly encouraging is the significant improvement in earnings: With CHF 125,785.97, the company was able to significantly increase its earnings compared to the same period last year (CHF -72,889.88), thereby impressively confirming the positive trajectory it has embarked upon.

This positive earnings trend underscores Vitruvia Medical AG's operational strength and progress. At the same time, the improved earnings situation creates a solid foundation for further development in the current fiscal year.

Based on the company's business performance in line with plans and the positive trend in the first half of the year, management confirms its positive outlook for the full year 2026 and believes the company remains well-positioned to achieve its targets.

LT technologies GmbH & Co. KG, a wholly owned subsidiary of Vitruvia Medical AG, looks back on a strong first half of 2026. The half-year revenue target of €1,300,000 was achieved as planned, putting the company on a stable course to meet its full-year target of €2.6 million.

Another important milestone was the successful completion of the surveillance audit in July in accordance with DIN EN ISO 13485:2021. This successful certification confirms the effectiveness of our quality management system and underscores our high quality standards.

Our partnership with a German full-service provider has been successfully established and is being continuously expanded. This opens up additional opportunities for sustainable business growth.

The positive revenue growth in the first half of the year was achieved primarily with our existing customers. This underscores the high level of customer satisfaction as well as the long-term, trusting partnership with our business partners.

In addition, we were able to secure a new major customer from Norway for the second half of the year. This contract strengthens our international market presence and will make a positive contribution to further revenue growth.

LT continues to be on a growth trajectory. In addition to the successful performance of the current fiscal year, we are already working intensively on new projects for 2027, thereby laying the foundation for sustainable corporate growth.

Anglikon, August 12, 2026

Vitruvia Medical AG
Board of Directors